Return to homepagePandemic Pact

EMCOVID-19: Multiple Sclerosis and COVID-19

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00948

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Luís Brieva Ruiz

  • Research Location

    Spain

  • Lead Research Institution

    INSTITUTO INV. BIOMEDICA DE LLEIDA. FUNDACION DR. PIFARRE (IRBLLEIDA)

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Individuals with multimorbidityOther

  • Occupations of Interest

    Unspecified

Abstract

MS is an autoimmune disease and its interaction with COVID-19 infection has not yet been studied. This is important for several reasons. 1) COVID-19 infection could modify the evolution of MS 2) MS could alter the response to COVID-19. Nor has the evolution of the infection been studied according to the immunomodulatory treatment (TME) received and whether it alters the evolution of MS. In this we intend to study a) how the infection by SARS-COV-2 affects the clinical and immunological status of patients with MS based on the characteristics of their MS and the MSD they take, b) how MS and MSD treatment influence in the appearance and development of the SARS-COV-2 infection and c) if there are beneficial effects of some MSDs in the evolution of the SARS-COV-2 infection or if some drugs used in the treatment of the infection could be beneficial for treating MS.